Propel Bio Management »

Nektar Therapeutics shares owned by Propel Bio Management

Quarter-by-quarter ownership of Nektar Therapeutics (NKTR) shares owned by Propel Bio Management from 13F filings

Historical chart of Propel Bio Management investment in Nektar Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Nektar Therapeutics held by Propel Bio Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Nektar Therapeutics by Propel Bio Management

Quarter filed Position value Share count Share price at filing
2025-09-30 $2.8M 49k 56.90

More positions owned by Propel Bio Management

Plains Gp Holdings Lp-cl Ltd Partnr Int A (PAGP)
Achieve Life Sciences (ACHV)
Akero Therapeutics (AKRO)
Milestone Pharmaceuticals (MIST)
Applied Therapeutics (APLT)
Phathom Pharmaceuticals (PHAT)
Abeona Therapeutics Com New (ABEO)
Delcath Systems Com New (DCTH)
Celldex Therapeutics Com New (CLDX)
Tscan Therapeutics (TCRX)
Compass Pathways Sponsored Ads (CMPS)
Nektar Therapeutics Com New (NKTR)
Jasper Therapeutics Com New (JSPR)
Zevra Therapeutics Com New (ZVRA)
Miragen Therapeutics (VRDN)

View all positions for Propel Bio Management

Top funds holding Nektar Therapeutics

Susquehanna International
BVF
Vanguard Group
Citadel Advisors
Farallon Capital Management
BlackRock
Millennium Management
Two Sigma Investments
Nantahala Capital Management
22NW
Emerald Advisers
Leucadia National Corporation
Dr. Jeffrey R. Jay, M.D.
PRIMECAP Management Company
Renaissance Technologies

View all funds holding Nektar Therapeutics